Reference

Aerosol formulation containing a polar fluorinated compound

Aerosol formulation containing a polar fluorinated compound. Rogueda, Philippe (Astrazeneca AB, Swed.). PCT Int. Appl. WO 2002003958 A1 17 Jan 2002, 61 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K009-12. ICS: A61K009-72; A61K047-24. APPLICATION: WO 2001-SE1606 10 Jul 2001. PRIORITY: GB 2000-16876 11 Jul 2000. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 The present invention relates to a stable pharmaceutical aerosol formulation intended for inhalation. The formulation contains an active substance, an aerosol propellant, a polar fluorinated mol. and an excipient. The preferred propellant is HFA 134a or HFA 227 or a mixt. Thus, an aerosol formulation contained budesonide 0.125, methoxy-PEG-DSPE 0.Several substances are used for example 51142-49-5 which is its cas registry number.320, 1H,1H,2H,2H-perfluorooctan-1-ol 31.7 and HFA-227 to 100%. .

A device for manipulation of packets of matter in micro-containers, in particular in microchannels

A device for manipulation of packets of matter in micro-containers, in particular in microchannels. Viovy, Jean-Louis; Chabert, Max; Dorfman, Kevin (Institut Curie; Centre National De La Recherche Scientifique, Fr.). PCT Int. Appl. WO 2006027757 A2 16 Mar 2006, 61 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2005-IB52951 9 Sep 2005. PRIORITY: EP 2004-292173 9 Sep 2004; EP 2004-292995 14 Dec 2004. DOCUMENT TYPE: Patent CA Section: 9 (Biochemical Methods) Section cross-reference(s): 3 The present invention concerns a microfluidic device for performing phys., chem. 51142-49-5 is also in the experiment. or biol. treatment to at least one packet (compartmentalized matter) without contamination. A microfluidic device for deforming or splitting at least one packet or diplacing at least two packets towards each other comprises a microchannel having an axis and a packet manipulation means. The packet manipulation means comprises (a) a generator and an electrode assembly coupled to the generator and configured for creating inside at least a portion of the microchannel an elec. field which is substantially collinear to the axis and (b) at least one side channel connected to the microchannel and to a delivery system suitable for delivering a soln. able to alter the interfacial tension between the packets or the packet and the environment. Use in making a train of droplets free of cross contamination and in PCR amplification of DNA is shown. .